MY135375A - Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases - Google Patents

Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases

Info

Publication number
MY135375A
MY135375A MYPI20034144A MYPI20034144A MY135375A MY 135375 A MY135375 A MY 135375A MY PI20034144 A MYPI20034144 A MY PI20034144A MY PI20034144 A MYPI20034144 A MY PI20034144A MY 135375 A MY135375 A MY 135375A
Authority
MY
Malaysia
Prior art keywords
pyrimidine
dicarboxylic acid
acid diamides
selectively inhibiting
collagenases
Prior art date
Application number
MYPI20034144A
Inventor
Otmar Dr Klingler
Reinhard Dr Kirsch
Joerg Dr Habermann
Klaus-Ulrich Dr Weithmann
Christan Dr Engel
Bernard Dr Pirard
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10251019A external-priority patent/DE10251019A1/en
Priority claimed from DE10254092A external-priority patent/DE10254092A1/en
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MY135375A publication Critical patent/MY135375A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PYRIMIDINE-4,6-DICARBOXYLIC ACID DIAMIDES OF THE FORMULA I ARE SUITABLE FOR SELECTIVELY INHIBITING COLLAGENASE (MMP 13). THE PYRIMIDINE-4,6-DICARBOXYLIC ACID DIAMIDES CAN THEREFORE BE USED FOR TREATING DEGENARATIVE JOINT DISEASES.
MYPI20034144A 2002-11-02 2003-10-30 Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases MY135375A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10251019A DE10251019A1 (en) 2002-11-02 2002-11-02 New pyrimidine-4,6-dicarboxamide derivatives, are selective collagenase inhibitors useful e.g. for treating degenerative joint diseases, connective tissue disorders or cancer
DE10254092A DE10254092A1 (en) 2002-11-20 2002-11-20 New pyrimidine-4,6-dicarboxamide derivatives, are selective collagenase inhibitors useful e.g. for treating degenerative joint diseases, connective tissue disorders or cancer

Publications (1)

Publication Number Publication Date
MY135375A true MY135375A (en) 2008-04-30

Family

ID=32313538

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20034144A MY135375A (en) 2002-11-02 2003-10-30 Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases

Country Status (25)

Country Link
EP (1) EP1560815B1 (en)
JP (1) JP4564359B2 (en)
KR (1) KR101050680B1 (en)
AR (1) AR043058A1 (en)
AT (1) ATE388941T1 (en)
AU (1) AU2003301847A1 (en)
BR (1) BR0315055A (en)
CA (1) CA2504153C (en)
CO (1) CO5700759A2 (en)
DE (1) DE50309381D1 (en)
DK (1) DK1560815T3 (en)
ES (1) ES2298621T3 (en)
HK (1) HK1083503A1 (en)
HR (1) HRP20050382B1 (en)
MA (1) MA27412A1 (en)
MX (1) MXPA05004365A (en)
MY (1) MY135375A (en)
NO (1) NO330345B1 (en)
PE (1) PE20040605A1 (en)
PL (1) PL375044A1 (en)
PT (1) PT1560815E (en)
RS (1) RS20050294A (en)
RU (1) RU2344129C2 (en)
TW (1) TWI316512B (en)
WO (1) WO2004041788A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
EA013525B1 (en) * 2005-05-20 2010-06-30 Алантос-Фармасьютикалз Холдинг, Инк. Heterobicyclic metalloprotease inhibitors and use thereof
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
CA2658362A1 (en) * 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
CL2008001933A1 (en) 2007-06-29 2009-09-25 Millennium Pharm Inc Pyrimidine derived compounds, raph kinase inhibitors; intermediate compounds; preparation procedure; pharmaceutical composition; and its use to treat proliferative, cardiac, neurodegenerative, inflammatory, bone, immunological, viral disease, among others.
AR068509A1 (en) * 2007-09-19 2009-11-18 Jerini Ag BRADIQUININE B1 RECEIVER ANTAGOSNIST
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX2012012204A (en) 2010-04-22 2012-12-05 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds.
AR086113A1 (en) 2011-04-30 2013-11-20 Abbott Lab ISOXAZOLINS AS THERAPEUTIC AGENTS
ES2957761T3 (en) 2014-04-15 2024-01-25 Vertex Pharma Pharmaceutical compositions for the treatment of diseases mediated by the cystic fibrosis transmembrane conductance regulator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931432A1 (en) * 1989-09-21 1991-04-04 Hoechst Ag PYRIMIDIN-4,6-DICARBONSAEUREDIAMIDE, METHOD FOR THE PRODUCTION AND USE THEREOF AND MEDICINAL PRODUCTS BASED ON THESE COMPOUNDS
EP1368323B1 (en) 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine matrix metalloproteinase inhibitors
DOP2002000332A (en) * 2001-02-14 2002-08-30 Warner Lambert Co MATRIX METALOPROTEINAS PYRIDINE INHIBITORS
DE10160357A1 (en) * 2001-12-08 2003-06-18 Aventis Pharma Gmbh Use of pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides for the selective inhibition of collagenases

Also Published As

Publication number Publication date
HRP20050382B1 (en) 2013-09-30
NO20052628L (en) 2005-07-08
HRP20050382A2 (en) 2006-12-31
EP1560815A1 (en) 2005-08-10
RU2005116847A (en) 2006-01-20
KR101050680B1 (en) 2011-07-21
AU2003301847A1 (en) 2004-06-07
JP4564359B2 (en) 2010-10-20
CA2504153C (en) 2012-07-03
CO5700759A2 (en) 2006-11-30
PE20040605A1 (en) 2004-10-15
JP2006513158A (en) 2006-04-20
RU2344129C2 (en) 2009-01-20
BR0315055A (en) 2005-08-16
DK1560815T3 (en) 2008-06-16
HK1083503A1 (en) 2006-07-07
PL375044A1 (en) 2005-11-14
ES2298621T3 (en) 2008-05-16
DE50309381D1 (en) 2008-04-24
CA2504153A1 (en) 2004-05-21
PT1560815E (en) 2008-04-07
MXPA05004365A (en) 2005-07-05
NO330345B1 (en) 2011-03-28
TWI316512B (en) 2009-11-01
WO2004041788A1 (en) 2004-05-21
NO20052628D0 (en) 2005-05-31
KR20050067212A (en) 2005-06-30
EP1560815B1 (en) 2008-03-12
TW200418808A (en) 2004-10-01
ATE388941T1 (en) 2008-03-15
RS20050294A (en) 2007-11-15
MA27412A1 (en) 2005-06-01
AR043058A1 (en) 2005-07-13

Similar Documents

Publication Publication Date Title
HRP20050382B1 (en) Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases
MY135841A (en) Novel benzodioxoles
GB0209891D0 (en) Novel compounds
GB9801690D0 (en) Therapeutic agents
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
MXPA04001088A (en) Pyrazole-derived kinase inhibitors and uses thereof.
MXPA03009750A (en) Chemical compounds.
DK1173439T3 (en) Haloalkoxy-imidazonaphthyridiner
MXPA04005129A (en) Use of pyridine-2,4-dicarboxylic acid diamides and of pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition.
ES2249309T3 (en) COMPOUNDS OF 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA AS INHIBITORS OF CSBP / P39 KINASA.
TR200201128T2 (en) Tetrahydrothiopyraniphalazinone derivatives as PDE4 inhibitors.
AP2000001761A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
NO984950L (en) Compounds with growth hormone releasing properties
TW200505906A (en) Selective mmp-13 inhibitors
MXPA02012263A (en) 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect.
SE9903290D0 (en) Novel compounds
ATE287403T1 (en) 6-PHENYLBENZONAPHTHYIDINE
DK1244643T3 (en) tryptase
DK1244614T3 (en) Tryptase inhibitors
MY140194A (en) Novel fusidic acid derivatives
ID27656A (en) AZABISIKLOHEPTANA N-SUBSTITUTIONAL DERIVES, THE PRODUCTION AND USE OF IT
DE60216920D1 (en) Tryptase-inhibitoren
PT1358182E (en) DERIVATIVES OF DIAZOCINES AND THEIR USE AS TRIPTASE INHIBITORS
SI0937075T1 (en) New Imidazo- and Oxazolopyridines as Phosphodiesterase Inhibitors.
RS20050181A (en) Novel benzonaphthyridines